Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant XELOX followed by chemoradiotherapy for locally advanced esophagogastric junction carcinoma
2013-001630-18Phase 2Terminated
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in esophagogastric junction cancer, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: pathological complete response rate. Started Jun 2013; status: terminated.
02
Drugs
oxaliplatincapecitabine
03
Conditions
esophagogastric junction cancer
Beyond the preview
Go deeper on 2013-001630-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001630-18.